

Novartis India Limited
Registered Office:
Inspire BKC
Part of 601 & 701
Bandra Kurla Complex
Bandra (East)
Mumbai – 400 051
Maharashtra, India
Tel +91 22 50243000
Fax +91 22 50243010
Email: india.investors@novartis.com
CIN No. L24200MH1947PLC006104

Website: www.novartis.in

March 31, 2022

To,
The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001
Scrip code: 500672

- Sub.: 1. <u>Intimation of meeting of the Board of Directors of Novartis India Limited</u> ("the Company")
 - 2. Closure of Trading Window
- Ref.: 1. Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
 - 2. Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015

Dear Sir/ Madam,

Please be informed that the meeting of the Board of Directors of the Company is scheduled to be held on Thursday, May 19, 2022, to *inter alia* consider the Audited financial results of the Company for the fourth quarter and financial year ending on March 31, 2022 ("said results") and recommendation of final dividend on Equity Share, if any, for the said year.

In this connection, further note that pursuant to the Company's Code of Conduct to regulate, monitor and report share trading by Insiders ["the Code"], the trading window for dealing in securities of the Company shall remain closed from Friday, April 1, 2022 to Saturday, May 21, 2022 (both days inclusive).

The same is being duly communicated to all the Designated Persons under the Code which is available on the Company's website i.e. www.novartis.in.

This is for your information.

Thanking You.

Yours sincerely,

For Novartis India Limited

Monaz

Diplatly ingent by Monaz Noibe

Procedul, enferont and the Control of the Co